Multi-Omics-Based Analysis of the Effect of Longevity Genes on the Immune Relevance of Colorectal Cancer

<b>Background</b>: Colorectal cancer (CRC) ranks as the third most prevalent cancer globally, with its incidence and recurrence rates steadily rising. To explore the relationship between CRC and longevity-associated genes (LAGs), and to offer new therapeutic avenues for CRC treatment, we developed a prognostic model based on these genes to predict the outcomes for CRC patients. Additionally, we conducted an immune correlation analysis. <b>Methods</b>: We conducted a comprehensive analysis of the effects of 81 LAGs in CRC by integrating multiple omics datasets. This analysis led to the identification of two distinct molecular subtypes and revealed that alterations in LAGs across various layers were linked to clinicopathological features, prognosis, and cell infiltration characteristics within the tumor microenvironment (TME). The training and validation cohorts for the models were derived from the TCGA-COAD, TCGA-READ, and GSE35279 datasets. Subsequently, we developed a risk score model, and the Kaplan-Meier method was employed to estimate overall survival (OS). Ultimately, we established a prognostic model based on five LAGs: <i>BEDN3</i>, <i>EXOC3L2</i>, <i>CDKN2A</i>, <i>IL-13</i>, and <i>CAPN9</i>. Furthermore, we assessed the correlations between the risk score and factors such as immune cell infiltration, microsatellite instability, and the stem cell index. <b>Results</b>: Our comprehensive bioinformatics analysis revealed a strong association between longevity genes and CRC. The risk score derived from the five newly identified LAGs was determined to be an independent prognostic factor for CRC. Patients categorized by this risk score demonstrated significant differences in immune status and microsatellite instability. <b>Conclusions</b>: Our comprehensive multi-omic analysis of LAGs highlighted their potential roles in the tumor immune microenvironment, clinicopathological features, and prognosis, offering new insights for the treatment of CRC.